Eric Lattman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kochi-based pharma firm's new drug shows 'promising' results against COVID-19 The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore PB Jayakumar | February 22, 2021 | Updated 15:08 IST GPP-Baladol, a novel chemical entity (NCE) being developed by pharmaceutical research firm PNB Vesper Life Science for treating Covid-19 patients, claims to have shown promising results in the Phase 2b clinical trials. The pharma firm will soon seek Indian drug regulators' approval ...

PNB Vesper provides potential option to save hospitalised COVID-19 patients globally PNB Vesper provides potential option to save hospitalised COVID-19 patients globally 12 February 2021 | News Source credit: Shutterstock PNB Vesper, a leading Kerala based life sciences company, has announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 Clinical trial of GPP-BALADOL in COVID-19 moderate patients with ox...

Kerala firm successfully completes Phase 2 trials of Covid drug ​ By IANS | Published on ​ Thu, Feb 11 2021 22:57 IST | ​ 0 Views   Despite the widespread use of oral contraceptives (OCPs) by women, many are not aware that it may impair their ability to recognise others' emotional expressions, which may have serious consequences in interpersonal contexts, suggests a new study.. Image Source: IANS News Kochi, Feb 11 : PNB Vesper, a leading Kerala-based life sciences company, on Thursday announced that it has successfully completed the Phase 2 clinical trials of its proprietary drug...